CAESAREA, Israel, July 25, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that following new data presented at the American Diabetes Association (ADA) on June 25, 2018 showing long-term sustainable clinical results, the Company has launched new product offerings and enhancements to promote the long-term use of its digital health platform.

DarioHealth has added key features to its business-to-consumer application, site, its shop, and the Dario Engage digital platform, designed to create higher levels of user engagement. A new annual membership plan is directly aligned with data recently presented at ADA.

DarioHealth recently announced very compelling data from over 17,000 people who used its integrated digital health solution in 2017. Users with Type 2 diabetes saw a 19% reduction in the average ratio of high glucose events and an 11% increase in the ratio of normal range readings. The data also showed even higher improvement in glucose levels with sustainable results when users were on the system for a year or more.

"The results presented at the ADA conference prompted us to offer an annual plan and make it even simpler for users to sign up for in-app and premium purchases that are designed to increase their engagement," commented Erez Raphael, President and CEO of DarioHealth.

"We are committed to providing all our members with easier access to the Dario tools, and support that enable them to simply balance their lives," added DarioHealth's Vice President of Marketing, João Mendes-Roter.

About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes new offerings and enhancements to promote the long-term use of its platform, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Joao Mendes-Roter
VP Marketing
joao@mydario.com 
1-914-775-5548

DarioHealth Investor Relations Contact:
Westwicke Partners
Dario@Westwicke.com
1-443-213-0500

SOURCE DarioHealth Corp.